drugset / Trial / NCT00019994

Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00019994

Open-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic melanoma that has not responded to previous therapy.

Timeline

Start
1999-10
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MART-1 antigen Vaccine Subcutaneous
Subject gp100 antigen Peptide
Background aldesleukin Protein / enzyme biologic Intravenous
Background incomplete Freund's adjuvant Other / unclassified Subcutaneous

Indications